Immune responses of mice with different genetic backgrounds to improved multiepitope, multitarget malaria vaccine candidate antigen FALVAC-1A

Clinical and Vaccine Immunology

Volumn 15, Issue 11, 2008, Pages 1674-1683

  Kaba, S A ^a,c   Price, A ^a,b   Zhou, Z ^a,b   Sundaram, V ^a   Schnake, P ^a   Goldman, I F ^a   Lal, A A ^a   Udhayakumar, V ^a   Todd, C W ^a,b  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b ATLANTA RESEARCH AND EDUCATION FOUNDATION   (United States)

^c WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM PHOSPHATE; COPOLYMER; CRL 1005; FALVAC 1A ANTIGEN; GAMMA INTERFERON; IMMUNOGLOBULIN G1; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 4; MALARIA VACCINE; MONTANIDE ISA 720; QS 21; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG FORMULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOGLOBULIN PRODUCTION; INTERFERON PRODUCTION; MOUSE; MOUSE STRAIN; NONHUMAN; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES; FEMALE; IMMUNOGLOBULIN G; INTERFERON-GAMMA; INTERLEUKIN-4; LYMPHOCYTES; MALARIA VACCINES; MICE; MICE, INBRED C57BL; MICE, INBRED ICR; PLASMODIUM FALCIPARUM; SPLEEN; VACCINES, SYNTHETIC;

EID: 55849097299     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00164-08     Document Type: Article

References (45)

1. Ahlborg, N., I. T. Ling, A. A. Holder, and E. M. Riley. 2000. Linkage of exogenous T-cell epitopes to the 19-kilodalton region of Plasmodium yoelii merozoite surface protein 1 (MSP119) can enhance protective immunity against malaria and modulate the immunoglobulin subclass response to MSP119. Infect. Immun. 68:2102-2109.
2. + Th-1 type T-cell peptide epitopes from herpes simplex virus glycoprotein D that confer protective immunity. J. Virol. 77:9463-9473.
3. Cai, Q. L., F. Wei, Y. H. Lin, D. D. Shao, and H. Wang. 2004. Immunogenicity of polyepitope libraries assembled by epitope shuffling: an approach to the development of chimeric gene vaccination against malaria. Vaccine 23: 267-277.
4. Carvalho, L. H., J. C. R. Hafalla, and F. Zavala. 2001. ELISPOT assay to measure antigen-specific murine CD8+ T cell responses. J. Immunol. Methods 252:207-218.
5. Cribbs, D. H., A. Ghochikyan, V. Vasilevko, M. Tran, I. Petrushina, N. Sadzikava, D. Babikyan, P. Kesslak, T. Kieber-Emmons, C. W. Cotman, and M. G. Agadjanyan. 2003. Adjuvant-dependent modulation of Th1 and Th2 response to immunization with β-amyloid. Int. Immunol. 15:505-514.
6. de Oliveira, G. A., P. Clavijo, R. S. Nussenzweig, and E. H. Nardin. 1994. Immunogenicity of an alum-adsorbed synthetic multiple-antigen peptide based on B- and T-cell epitopes of Plasmodium falciparum CS protein: possible vaccine application. Vaccine 12:1012-1017.
7. De Souza, J. B., I. T. Ling, S. A. Ogun, A. A. Holder, and J. H. Playfair. 1996. Cytokines and antibody subclass associated with protective immunity against blood-stage malaria in mice vaccinated with the C terminus of merozoite surface protein 1 plus a novel adjuvant. Infect. Immun. 64:3532-3536.
8. Eisenbarth, S. C., O. R. Colegio, W. O'Connor, Jr., F. S. Sutterwala, and R. A. Flavell. 2008. Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminum adjuvants. Nature 453:1122-1126.
9. Good, M. F., H. Xu, M. Wykes, and C. R. Engwerda. 2005. Development and regulation of cell-mediated immune responses to the blood stages of malaria: implications for vaccine research. Annu. Rev. Immunol. 23:69-99.
10. Guy, B., T. Krell, V. Sanchez, A. Kennel, C. Manin, and R. Sodoyer. 2005. Do Th1 and Th2 sequence motifs exist in proteins? Identification of amphipathic immunomodulatory domains in Helicobacter pylori catalase. Immunol. Lett. 96:261-275.
11. Habjanec, L., B. Halassy, and J. Tomasic. 2008. Immunomodulatory activity of novel adjuvant formulations based on Montanide ISA oil-based adjuvants and peptidoglycan monomer. Int. Immunopharmacol. 8:717-724.
12. Haro, I., and M. J. Gomara. 2004. Design of synthetic peptidic constructs for the vaccine development against viral infections. Curr. Protein Pept. Sci. 5:425-433.
13. Hirunpetcharat, C., J. H. Tian, D. C. Kaslow, N. van Rooijen, S. Kumar, J. A. Berzofsky, L. H. Miller, and M. F. Good. 1997. Complete protective immunity induced in mice by immunization with the 19-kilodalton carboxyl-terminal fragment of the merozoite surface protein-1 (MSP119) of Plasmodium yoelii expressed in Saccharomyces cerevisiae: correlation of protection with antigen-specific antibody titer, but not with effector CD4+ T cells. J. Immunol. 159:3400-3411.
14. Hisaeda, H., K. Yasutomo, and K. Himeno. 2005. Malaria: immune evasion by parasites. Int. J. Biochem. Cell Biol. 37:700-706.
15. Hoffman, S. L., and L. M. Miller. 1996. Perspectives on malaria vaccine development, p. 1-13. In S. L. Hoffmann (ed.), Malaria vaccine development: a multi-immune response approach. American Society for Microbiology, Washington, DC.
16. Hoover, D. M., and J. Lubkowski. 2002. DNAWorks: an automated method for designing oligonucleotides for PCR-based gene synthesis. Nucleic Acids Res. 30:e43.
17. Hui, G. S., and C. N. Hashimoto. 1998. Pathways for potentiation of immunogenicity during adjuvant-assisted immunizations with Plasmodium falciparum major merozoite surface protein 1. Infect. Immun. 66:5329-5336.
18. Jouvin-Marche, E., M. G. Morgado, C. Leguern, D. Voegtle, F. Bonhomme, and P. A. Cazenave. 1989. The mouse Igh-1a and Igh-1b H chain constant regions are derived from two distinct isotypic genes. Immunogenetics 29:92-97.
19. Kenney, R. T., N. R. Rabinovich, S. Pichyangkul, V. L. Price, and H. D. Engers. 2002. 2nd meeting on novel adjuvants currently in/close to human clinical testing. World Health Organization - Organisation Mondiale de la Santé Fondation Mérieux, Annecy, France, 5-7 June 2000. Vaccine 20:2155-2163.
20. Kool, M., T. Soullie, M. van Nimwegen, M. A. M. Willart, F. Muskens, S. Jung, H. C. Hoogsteden, H. Hammad, and B. N. Lambrecht. 2008. Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells. J. Exp. Med. 205:869-882.
21. Lee, E. A. M., D. R. Palmer, K. L. Flanagan, W. H. H. Reece, K. Odhiambo, K. Marsh, M. Pinder, M. B. Gravenor, W. A. Keitel, K. E. Kester, C. Diggs, D. Kaslow, V. Apostolopoulos, W. R. Ballou, A. V. S. Hill, U. Krzych, and M. Plebanski. 2002. Induction of T helper type 1 and 2 responses to 19-kilodalton merozoite surface protein 1 in vaccinated healthy volunteers and adults naturally exposed to malaria. Infect. Immun. 70:1417-1421.
22. Li, H., S. B. Willingham, J. P.-Y. Ting, and F. Re. 2008. Inflammasome activation by alum and alum's adjuvant effect are mediated by NLRP3. J. Immunol. 181:17-21.
23. Livingston, B., C. Crimi, M. Newman, Y. Higashimoto, E. Apella, J. Sidney, and A. Sette. 2002. A rational strategy to design multiepitope immunogens based on multiple Th lymphocyte epitopes. J. Immunol. 168:5499-5506.
24. Livingston, B. D., M. Newman, C. Crimi, D. McKinney, R. Chesnut, and A. Steele. 2001. Optimization of epitope processing enhances immunogenicity of multiepitope DNA vaccines. Vaccine 19:4652-4660.
25. Lyon, J. A., E. Angov, M. P. Fay, J. S. Sullivan, A. S. Girourd, S. J. Robinson, E. S. Bergmann-Leitner, E. H. Duncan, C. A. Darko, W. E. Collins, C. A. Long, and J. W. Barnwell. 2008. Protection induced by Plasmodium falciparum MSP142 is strain-specific, antigen and adjuvant dependent, and correlates with antibody responses. PLoS One 3:e2830.
26. Martin, R. M., J. L. Brady, and A. M. Lew. 1998. The need for IgG2c specific antiserum when isotyping antibodies from C57BL/6 and NOD mice. J. Immunol. Methods 212:187-192.
27. Mata, E., A. M. Carcaboso, R. M. Hernández, M. Igartua, G. Corradin, and J. L. Pedraz. 2007. Adjuvant activity of polymer microparticles and Montanide ISA 720 on immune responses to Plasmodium falciparum MSP-2 long synthetic peptides in mice. Vaccine 25:877-885.
28. Matsumoto, S., H. Yukitake, H. Kanbara, and T. Yamada. 1999. Long-lasting protective immunity against rodent malaria parasite infection at the blood stage by recombinant BCG secreting merozoite surface protein-1. Vaccine 18:832-834.
29. Morokata, T., J. Ishikawa, and T. Yamada. 2000. Antigen dose defines T helper 1 and T helper 2 responses in the lungs of C57BL/6 BALB/c mice independently of splenic responses. Immunol. Lett. 72:119-126.
30. National Research Council. 1996. Guide for the care and use of laboratory animals. National Academy Press, Washington, DC.
31. Osorio, Y., J. Cohen, and H. Ghiasi. 2004. Improved protection from primary ocular HSV-1 infection and establishment of latency using multigenic DNA vaccines. Investig. Ophthalmol. Vis. Sci. 45:506-514.
32. Pink, J. R., and M.-P. Kieny. 2004. 4th meeting on novel adjuvants currently in/close to human clinical testing. World Health Organization- Organisation Mondiale de la Santé Fondation Mérieux, Annecy, France, 23-25 June 2003. Vaccine 22:2097-2102.
33. Rafi-Janajreh, A., J. E. Tongren, C. Kensil, C. Hackett, F. Candal, A. A. Lal, and V. Udhayakumar. 2002. Influence of adjuvants in inducing immune response to different epitopes included in a multiepitope, multivalent, multistage Plasmodium falciparum candidate vaccine (FALVAC-1) in outbred mice. Exp. Parasitol. 101:3-12.
34. Rogers, P. R., and M. Croft. 2000. CD28, Ox-40, LFA-1, and CD4 modulation of Th1/Th2 differentiation is directly dependent on the dose of antigen. J. Immunol. 164:2955-2963.
35. Sachdeva, S., G. Ahmad, P. Malhotra, P. Mukherjee, and V. S. Chauhan. 2004. Comparison of immunogenicities of recombinant Plasmodium vivax merozoite surface protein 1 19- and 42-kilodalton fragments expressed in Escherichia coli. Infect. Immun. 72:5775-5782.
36. Sadler, K., W. Zeng, and D. C. Jackson. 2002. Synthetic peptide epitope-based polymers: controlling size and determining the efficacy of epitope incorporation. J. Pept. Res, 60:150-158.
37. Shi, Y. P., P. Das, B. Hollway, V. Udhayakumar, J. E. Tongren, F. Candal, S. Biswas, R. Ahmad, S. E. Hasnain, and A. A. Lal. 2000. Development, expression, and murine testing of a multistage Plasmodium falciparum malaria vaccine candidate. Vaccine 18:2902-2914.
38. Shi, Y. P., S. E. Hasnain, J. B. Sacci, B. P. Hollway, H. Fujioka, N. Kumar, R. Wohlhueter, S. L. Hoffman, W. Collins, and A. A. Lal. 1999. Immunogenicity and in vitro protective efficacy of a recombinant multistage Plasmodium falciparum candidate vaccine. Proc. Natl. Acad. Sci. USA 96:1615-1620.
39. Sugauchi, F., R. Y.-H. Wang, Q. Qi, B. Jin, H. J. Alter, and J. Y.-H. Richard, Q. Q. Wang, J. Bo, A. Harvey, and J. W.-K. Shih. 2006. Vigorous hepatitis C virus-specific CD4+ and CD8+ T cell response induced by protein immunization in the presence of Montanide ISA-720 plus synthetic oligodeoxynucleotides containing immunostimulatory cytosine-guanine dinucleotide motifs. J. Infect. Dis. 193:563-572.
40. Theisen, D. M., F. B. Bouche, K. C. El Kasmi, I. von der Ahe, W. Ammerlaan, S. Demotz, and C. P. Muller. 2000. Differential antigenicity of recombinant polyepitope-antigens based on loop-and helix-forming B and T cell epitopes. J. Immunol. Methods 242:145-157.
41. Tian, J. H., L. H. Miller, D. C. Kaslow, J. Ahlers, M. F. Good, D. W. Alling, J. A. Berzofsky, and S. Kumar. 1996. Genetic regulation of protective immune response in congenic strains of mice vaccinated with a subunit malaria vaccine. J. Immunol. 157:1176-1183.
42. Velders, M. P., S. Weijzen, G. L. Eiben, A. G. Elmishad, P. M. Kloetzel, T. Higgins, R. B. Cicarelli, M. Evans, S. Man, L. Smith, and W. M. Kast. 2001. Defined flanking spacers and enhanced proteolysis is essential for eradication of established tumors by an epitope string DNA vaccine. J. Immunol. 166:5366-5373.
43. Vogel, F. R., and M. F. Powell. 1995. A compendium of vaccine adjuvants and excipients, p. 154-155, In M. F. Powell and M. J. Newman (ed.), Vaccine design: the subunit and adjuvant approach. Plenum Press, New York, NY.
44. Xiao, L., A. Rafi-Janajreh, P. Patterson, Z. Zhou, and A. A. Lal. 2002. Adjuvants and malaria vaccine development. Chem. Immunol. 80:343-365.
45. Zhou, Z., C. W. Todd, R. Wohlhueter, A. Price, L. Xiao, P. Schnake, P. Cullison, A. M. Martin, I. F. Goldman, C. R. Kensil, P. De La Vega, V. Udhayakumar, and A. A. Lal. 2006. Development, characterization and immunogenicity of a multistage, multivalent Plasmodium falciparum vaccine antigen (FALVAC-1A) expressed in Escherichia coli. Hum. Vaccines 2:14-23.